Berkshire's Greg Abel Sells UnitedHealth: Smart or Premature?

May 27, 2026

Bobby Quant Team

💡 Key Takeaway

Greg Abel's sale of UnitedHealth, despite a subsequent rally, reflects a prudent focus on valuation and execution risks over chasing momentum.

What Happened: A Portfolio Spring Cleaning

In Berkshire Hathaway's latest quarterly filing, Greg Abel, who now oversees 94% of the conglomerate's massive stock portfolio, conducted significant sales. The most notable exit was the complete sale of Berkshire's stake in UnitedHealth Group, a position of about 5.1 million shares acquired just last year.

This wasn't an isolated move. Abel also led Berkshire to exit positions in other well-known companies including Amazon, Mastercard, Visa, and Domino's Pizza. Many of these positions were likely initiated by former portfolio manager Todd Combs.

The proceeds from these sales were reportedly funneled into new and expanded holdings. Berkshire established new positions in Delta Air Lines and Macy's, and more than tripled its existing stake in Alphabet, the parent company of Google.

This activity marks one of the first major portfolio shifts under Abel's stewardship, signaling a move away from some legacy bets to fund new convictions. The sale of UnitedHealth is particularly eye-catching as it occurred just before the stock embarked on a significant rally.

What This Means for Me

If you hold UNH, this news introduces a notable headwind of sentiment, as a legendary investor's successor has voted with his feet. Monitor the company's ability to hit its growth targets closely. Investors with exposure to the managed care sector should note the increased scrutiny on valuations and execution. For holders of BRK.B or BRK.A, this activity confirms a new, more active management era is underway, which could lead to higher portfolio turnover.

Why It Matters: Valuation vs. Momentum

The sale matters because it pits a fundamental, valuation-focused investment philosophy against short-term price momentum. UnitedHealth's stock has surged over 40% since April 1st, driven by strong earnings and positive news on Medicare reimbursements.

On the surface, selling right before such a rally seems like a mistake. However, Abel's decision underscores a focus on risk and future execution. UnitedHealth's management has admitted its turnaround is still a work in progress, and the stock's current valuation of 21 times forward earnings hinges on achieving a forecasted 12.3% earnings growth.

If UnitedHealth fails to meet these elevated expectations or sustain double-digit growth, the stock is vulnerable to a sharp pullback. The company's ability to leverage AI for cost savings and secure future Medicare increases are key, yet uncertain, drivers.

For investors, this highlights the classic tension between trading on price action and investing on business fundamentals. Abel's move suggests Berkshire is prioritizing the latter, willing to forgo further gains if the risk/reward profile no longer aligns with its standards.

Stock to Watch

Stocks	Impact	Analysis
UNH	Negative	Berkshire's complete exit, despite a recent rally, signals caution on valuation and execution risks, potentially weighing on market sentiment.
GOOGL	Positive	Berkshire more than tripled its stake, showing strong conviction in Alphabet's long-term prospects.
GOOG	Positive	Berkshire more than tripled its stake, showing strong conviction in Alphabet's long-term prospects.
DAL	Positive	Berkshire initiated a new position, indicating Abel's team sees value in the airline sector.
M	Positive	Berkshire initiated a new position in Macy's, a vote of confidence in the retailer's turnaround potential.
AMZN	Neutral	Exit was part of broader portfolio trimming, not necessarily a negative view on Amazon's business.
MA	Neutral	Berkshire sold, but the long-term thesis for digital payments remains intact, making the impact neutral.
V	Neutral	Similar to Mastercard, the sale doesn't negate the strong secular tailwinds for the payments network.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.